Jan van Lieshout, MD

Nivolumab Plus Ipilimumab FDA Approved for MSI-H, dMMR Colorectal Cancer

Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA

Baseline LTF Linked With Treatment Response in SCLC